Recent Updates
Recently added Catalysts
JSPR Negative Sentiment Score: 30/100

JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Jasper Therapeutics Stockholders to Contact the Firm Regarding Filed Class Action

Key Takeaway: A class action lawsuit has been initiated against Jasper Therapeutics, Inc. for allegedly misleading investors about its business and operational practices. The lawsuit pertains to securities purchased between November 30, 2023, and July 3, 2025, and claims that the company failed to ensure compliance with critical manufacturing regulations. The allegations suggest this non-compliance may affect the outcomes of clinical studies, therefore inflating the perceived value of the company's prospects. Investors have until November 18, 2025, to apply as lead plaintiffs.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Jasper Therapeutics for misleading statements.
  • Allegations include failure to disclose manufacturing compliance issues.
  • Company's financial and clinical prospects possibly overstated.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ:JSPR) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”).
Investors have until November 18, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Jasper shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the deadline to apply as lead plaintiff in Jasper's lawsuit?

Potential lead plaintiffs must apply by November 18, 2025.

Who can participate in the Jasper class action lawsuit?

Anyone who acquired Jasper securities between November 30, 2023, and July 3, 2025.

How can investors contact Bragar Eagel & Squire for help?

Investors can call (212) 355-4648 or email investigations@bespc.com.

What allegations are made against Jasper Therapeutics?

The lawsuit claims false statements were made about Jasper's business and product safety.

What firm is handling the class action against Jasper?

The lawsuit is being handled by Bragar Eagel & Squire, P.C.

Last updated: Oct 25, 2025